Navigation Links
Aldea Pharmaceuticals Closes $24 Million Series B Financing
Date:8/24/2014

REDWOOD CITY, Calif., Aug. 25, 2014 /PRNewswire/ -- Aldea Pharmaceuticals, a company pioneering novel therapeutics to treat aldehyde metabolism disorders, today announced that it has closed a $24 million Series B equity financing. The financing included new investors RusnanoMedInvest (RMI) and WuXi PharmaTech Corporate Ventures. All previous investors including Canaan Partners and Correlation Ventures also participated in the round.

The financing will be used to advance Aldea's lead drug candidate, AD-6626, into clinical trials, including evaluating proof-of-concept for the treatment of subjects with acute alcohol intoxication and funding subsequent Phase 2 trials of intravenous (IV) AD-6626 in an emergency room (ER) setting. In addition, Aldea is studying oral AD-6626 for the treatment of subjects with the rare genetic disease Fanconi anemia, and anticipates the financing will support a Phase 1/2 proof-of-biology study in that indication.

Every year, millions of Americans are admitted to the ER as a result of clinically significant acute alcohol intoxication, and an estimated 10 to 15 percent of ER visits are associated with alcohol consumption. Acute alcohol toxicity can be life-threatening and can lead to ER crowding, delays in critical treatment for trauma patients and intensive use of hospital resources. Since there is no antidote treatment available for alcohol toxicity, patients with acute alcohol intoxication must wait for the alcohol to be metabolized from their systems before they can be discharged from the ER.

"The use of AD-6626 in the ER setting has the potential to stabilize patients suffering from acute alcohol toxicity and more rapidly improve the signs and symptoms of intoxication than waiting for alcohol metabolism, thereby simplifying patient care. This could facilitate treatment in individuals suffering from co-morbidities such as trauma, as well as benefiting the system as a whole," noted William Yelle, chief executive officer of Aldea. "We also have the opportunity to apply our scientific approach in the treatment of patients with Fanconi anemia, a rare genetic disease characterized by chromosomal instability, bone marrow failure and an increased risk of cancer. The funds we have secured with this financing should allow us to generate proof-of-concept data in both of these indications."

About Aldea Pharmaceuticals
Aldea Pharmaceuticals is focused on developing small molecule modulators of the aldehyde dehydrogenase enzyme superfamily. The scientific approach was discovered by Stanford University researchers and exclusively licensed to Aldea. Aldea is pursuing treatment of clinically significant acute alcohol toxicity, Fanconi anemia and other diseases and conditions associated with toxic aldehydes.


'/>"/>
SOURCE Aldea Pharmaceuticals
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
2. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
3. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
4. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
5. Icahn Issues Statement Regarding Amylin Pharmaceuticals
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
8. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
9. Jazz Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call On May 8, 2012
10. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
11. Avanir Pharmaceuticals To Present at Three Conferences In May
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... , June 30, 2017 In vitro diagnostics ... start of May, at least ten diagnostic companies have ... investments, public offerings and a loan facility.  The size ... almost $80 million.  Kalorama Information provides a monthly ... Diagnostics Knowledge Center. ...
(Date:6/30/2017)... -- Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing drug ... forms of existing biologically active molecule. ... Subveta oral spray ... formula, which is designed to prevent precipitation of the active ... provide fast onset of action and is designed to optimize ...
(Date:6/27/2017)... 2017   NuEyes (NuEyes Technologies Inc.) today announced ... its growth in helping the legally blind live more independent ... the leading developer of augmented, virtual and mixed reality smartglasses ... The undisclosed funding amount was provided by strategic partners as ... offices in Abu Dhabi , ...
Breaking Medicine Technology:
(Date:7/20/2017)... Orange, NJ (PRWEB) , ... July 20, 2017 , ... ... people wondering if herniated and bulging discs are the same thing. But it’s crucial ... in order to seek proper treatment, according to Kaixuan Liu, MD, PhD, founder and ...
(Date:7/20/2017)... ... 20, 2017 , ... A budget proposal to switch to an alternate consumer ... adjustment (COLA) is a bad deal for older and disabled Americans, says The ... grow even more slowly than the conventional one that is currently used to determine ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who are ... difficulties that face people who are missing teeth , he offers education about ... and bridges. Not only does an implant improve oral health, it also restores the ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... a $1.5 million Health Resources and Services Administration (HRSA) grant to train predoctoral ... special health care needs in rural and underserved areas. , The Predoctoral Pediatric ...
(Date:7/20/2017)... (PRWEB) , ... July 19, 2017 , ... ... “surprising habits” that may sometimes lead to, or worsen, varicose veins in some ... Center notes that, while avoiding certain not-so-good practices, like excessive sitting or standing, ...
Breaking Medicine News(10 mins):